BioSpace News Archive

Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024.

Novocure announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine.

Biodesix, Inc. today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share.

Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM, the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy, at the 73rd Annual American College of Cardiology Scientific Session taking place from April 6, 2024 –April 8, 2024 in Atlanta, GA.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM), at the 73rd Annual American College of Cardiology (ACC) Scientific Session taking place from April 6, 2024 –April 8, 2024.

Curis, Inc. today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares.

Leash Biosciences today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.

StageZero Life Sciences, Ltd. today announced further to its press release of April 2, 2024, that the Ontario Securities Commission (the “OSC”) has denied the Company’s application for a voluntary management cease trade order (the “MCTO”) as the Company does not meet the criteria for an MCTO.

Oxurion NV, a biopharmaceutical company headquartered in Leuven, made the following announcement regarding its financial calendar.